Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06672939 · ClinicalTrials.gov registry record · Phase 3
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
- 20
- Study locations
NCT06672939 is a Phase 3 study of Obesity and Overweight that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 125 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT06672939, a Phase 3 study of Obesity and Overweight, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study, performed under Master Protocol J4M-MC-PWMP, is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Orforglipron
Study Locations (20)
Other
- Shamir Medical Center - Beer Jacob
- Shaare Zedek Medical Center - Jerusalem
- Sheba Medical Center - Ramat Gan
- Azienda Ospedaliero Universitaria Meyer - Florence
- Azienda Ospedaliero Universitaria Maggiore della Carità - Novara
Texas
- Dynamed Clinical Research, LP d/b/a DM Clinical Research - Houston
- La Providence Pediatrics Clinic - Chemidox Clinical Trials - Houston
- Martin Diagnostic Clinic - Tomball
Connecticut
- Yale School of Medicine - Yale Diabetes Center (YDC)) Trials - New Haven
- Stamford Therapeutics Consortium - Stamford
California
- Carey Chronis MD Pediatric, Infant and Adolescent Medicine - Ventura
Georgia
- Children's Healthcare of Atlanta - Center for Advanced Pediatrics - Atlanta
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Louisiana
- Velocity Clinical Research - Lafayette
Mississippi
- MedPharmics, LLC - Gulfport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2027-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06672939
The ClinicalTrials.gov registry entry for NCT06672939 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (85% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06672939 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Texas, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06672939 about?
NCT06672939 is a clinical study titled "A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities". The main purpose of this study, performed under Master Protocol J4M-MC-PWMP, is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will las...
What is the current status of trial NCT06672939?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2024-11-18. Estimated completion is 2027-03.
What conditions does trial NCT06672939 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT06672939?
The interventions under investigation include: Placebo (DRUG), Orforglipron (DRUG).
Who is sponsoring clinical trial NCT06672939?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06672939 being conducted?
This trial has 20 study locations across California, Connecticut, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.